ARCT 2304
Alternative Names: LUNAR®-FLU; ARCT-2304; Self-Amplifying mRNA pandemic Influenza vaccineLatest Information Update: 30 Sep 2024
At a glance
- Originator Arcturus Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Dendritic cell modulators; Protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 19 Sep 2024 Arcturus Therapeutics plans a phase I trial for Influenza virus infections (Prevention) in December 2024 (IM, Injection) (NCT06602531)
- 05 Aug 2024 ARCT 2304 is available for licensing as of 05 Aug 2024. https://arcturusrx.com/mrna-medicines-pipeline/
- 05 Aug 2024 Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral), before August 2024 (Arcturus Therapeutics pipeline, August 2024)